Cereno Scientific obtains IND acceptance from FDA to start Phase II study with drug candidate CS1 in PAH
Cereno Scientific (XSAT: CRNO B) today announced that the US Food and Drug Administration (FDA) has accepted Cereno’s investigational new drug application (IND) for drug candidate CS1. This application was a collaborative effort with global partner Abbott for the IND opening study. The acceptance of the IND allows Cereno to start the planned Phase II study in patients with pulmonary arterial hypertension (PAH) at clinical sites in the US in accordance with the submitted study protocol.“This is a great milestone for the team and the company. We are excited to see our rare disease strategy